本院公開徵選「幹細胞外泌體(Exosomes from Stem Cells) 之疾病治療技術」專屬授權技術移轉廠商 NHRI technology, “Exosomes from Stem Cells for Treatment” available for technology licensing

一、 主旨:本院公開徵選「幹細胞外泌體(Exosomes from Stem Cells) 之疾病治療技術」專屬授權技術移轉廠商。NHRI technology, “Exosomes from Stem Cells for Treatment” (abbreviated as “The Technology”) available for technology licensing (exclusive license). 二、 技術說明本技術為一種由幹細胞衍生的再生醫學醫藥組合物(stem-based regeneration medicine),並非直接以細胞治療,而是以幹細胞產生出內含維持來源幹細胞特性所需之蛋白質及微核糖核酸之微脂體,作為疾病治療之生物藥。本技術已於動物試驗中證實,具治療中樞神經損傷及誘導組織再生之作用。The Technology is to use induced stem cell-derived exosomes, instead of stem cells, as regeneration medicine. The invention is a method of inducing stem…

Continue reading

Technology Available for Industry-Academia Collaboration or Technology Licensing. “Opioid Receptor Allosteric Modifier: DBPR116” (2021/1/28)

Title:NHRI technology, “Opioid Receptor Allosteric Modifier: DBPR116” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description:The Technology relates to antagonist-to-agonist allosteric modifiers (AAM) of a mu-opioid receptor (MOR) for treating an opioid receptor-associated condition. In the presence of this unique AAM (DBPR116), MOR could be selective activated…

Continue reading

NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” available for technology licensing (exclusive license), 2020/08/17

Subject NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” (abbreviated as “The Technology”) available for technology licensing (exclusive license). Description The Technology is to use induced stem cell-derived exosomes, instead of stem cells, as regeneration medicine. The invention is a method of inducing stem cells to release exosomes…

Continue reading

Technology Available for Technology Licensing. “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine(Jul 20,2020)

1.Title “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine” (abbreviated as “The Technology”) available for technology licensing. 2.Description: The present invention relates to a method for reducing the addictive andpsychotomimetic side effects of ketamine and enhancing the medical efficacy of ketamine. It is characterized…

Continue reading

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

技術移轉

1. Title: NHRI technology, “A Potential COVID-19 Therapeutic Compound” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: The Technology is a novel compound which, in coronaviral infected cells, targets the RNP complex containing viral RNA and nucleoprotein to block viral replication and activities for anti-coronaviral mechanism….

Continue reading